Repare Therapeutics reports Q4 EPS (67c), consensus (79c)

“Our recently implemented re-structuring and the re-prioritization of our clinical portfolio meaningfully extends our cash runway into late 2027. We are now focused on three ongoing Phase 1 clinical trials with readouts expected in 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor; the POLAR trial evaluating our RP-3467 Pol? ATPase inhibitor; and our ongoing MYTHIC trial evaluating lunresertib in combination with Debiopharm’s WEE1 inhibitor, Debio 0123,” said Lloyd Segal, president and CEO of Repare. “Our progress with RP-3467 Pol?i is particularly promising. We believe we are leading the field with helicase Pol0i – PARPi clinical combinations and look forward to sharing initial data by Q3 this year.”